Synthesis, SAR, Crystal Structure, and Biological Evaluation of Benzoquinoliziniums as Activators of Wild-Type and Mutant Cystic Fibrosis Transmembrane Conductance Regulator Channels

Journal of Medicinal Chemistry

Volumn 47, Issue 4, 2004, Pages 962-972

  Marivingt Mounir, Cécile ^a   Norez, Caroline ^a   Dérand, Renaud ^a   Bulteau Pignoux, Laurence ^a   Nguyen Huy, Dung ^b   Viossat, Bernard ^c   Morgant, Georges ^b   Becq, Frédéric ^a   Vierfond, Jean Michel ^a   Mettey, Yvette ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

10 CHLORO 6 HYDROXYBENZO[C]QUINOLIZINIUM CHLORIDE; 5 BUTYL 7 CHLORO 6 HYDROXYBENZO[C]QUINOLIZINIUM CHLORIDE; ASPARTIC ACID; BENZ[F]INDOLO[2,3 A]QUINOLIZINIUM SALT; BENZINDOLOQUINOLIZINE DERIVATIVE; BENZO[C]QUINOLIZINIUM; BENZOQUINOLIZINIUM DERIVATIVE; CALCIUM CHANNEL STIMULATING AGENT; CHLORIDE CHANNEL; GLYCINE; MPB 07; MUTANT PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL ASSAY; CELL TRANSPORT; CELL VOLUME; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HOMEOSTASIS; MISSENSE MUTATION; NONHUMAN; ROBOTICS; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ANIMALS; CHO CELLS; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MUTATION; QUINOLIZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10744229649     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0308848     Document Type: Article

References (44)

1. Riordan, J. R.; Rommens, J. M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J.-L.; Drumm, M. L.; Iannuzzi M. C.; Collins, F. S.; Tsui, L.-C. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989, 245, 1066-1073.
2. - channel in CHO cells stably expressing the cystic fibrosis gene. Nature 1991, 352, 628-631.
3. Quinton, P. M.; Physiological basis of Cystic Fibrosis: A Historical perspective. Physiol. Rev. 1999, 79, S3-S22.
4. Anderson, M. P.; Berger, H. A.; Rich, D. P.; Gregory, R. J.; Smith, A. E.; Welsh M. J. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991, 67, 775-784
5. Gadsby, D. C.; Nairn, A. C. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol. Rev. 1999, 79, S77-S107.
6. Welsh, M. J.; Smith, A. E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993, 73, 1251-1254.
7. Cutting, G. R.; Kasch, L. M.; Rosenstein, B. J.; Zielenski, J.; Tsui, L. C.; Antonarakis, S. E.; Kazazian, H. H. Jr. A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature 1990, 346, 366-369.
8. Smit, L. S.; Wilkinson, D. J.; Mansoura, M. K.; Collins, F. S.; Dawson, D. C. Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9963-9967.
9. Chang, X.-B.; Tabcharani, J. A.; Hou, Y. X.; Jensen, T. J.; Kartner, N.; Alon, N.; Hanrahan, J. W.; Riordan, J. R. Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. J. Biol. Chem. 1993, 268, 11304-11311.
10. Becq, F.; Jensen, T. J.; Chang, X.-B.; Savoia, A.; Rommens, J. M.; Tsui, L.-C.; Buchwald, M.; Riordan, J. R.; Hanrahan, J. W. Phosphatase inhibitors activate normal and defective CFTR CFT11 chloride channels. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9160-9164.
11. Logan, J.; Hiestand, D.; Daram, P.; Huang, Z.; Muccio, D. D.; Hartman, J.; Haley, B.; Cook, W. J.; Sorscher, E. J. Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J. Clin. Invest. 1994, 94, 228-236.
12. Howell, L. D.; Borchardt, R.; Cohn, J. A. ATP hydrolysis by a CFTR domain: Pharmacology and effects of G551D mutation. Bioche. Biophys. Res. Commun. 2000, 271, 518-525.
13. Li, C.; Ramjeesingh, M.; Wang, W.; Garami, E.; Hewryk, M.; Lee, D.; Rommens, J. M.; Galley, K.; Bear, C. E. ATPase activity of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 1999, 271, 28463-28468.
14. Becq, F.; Mettey, Y.; Gray, M. A.; Galietta, L. J.; Dormer, R. L.; Merten, M.; Metaye, T.; Chappe, V.; Marivingt-Mounir, C.; Zegarra-Moran, O.; Tarran, R.; Bulteau, L.; Derand, R.; Pereira, M. M.; McPherson, M. A.; Rogier, C.; Joffre, M.; Argent, B. E.; Sarrouilhe, D.; Kammouni, W.; Figarella, C.; Verrier, B.; Gola, M.; Vierfond, J.-M. Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J. Biol. Chem. 1999, 274, 27415-27425.
15. Dérand R.; Bultëau-Pignoux, L.; Mettey, Y.; Zegarra-Moran, O.; Howel, D.; Randak, C.; Galietta, L. J. V.; Cohn, J.; Norez, C.; Romio, L.; Vierfond, J.-M.; Joffre, M.; Becq, F. Activation of G551D CFTR channel with MPB-91: Regulation by ATPase activity and phosphorylation. Am. J. Physiol. 2000, 281, C1657-C1666.
16. Zegarra-Moran, O.; Romio, L.; Folli, C.; Caci, E.; Becq, F.; Vierfond, J.-M.; Mettey, Y.; Cabrini, G.; Fanen, P.; Galietta, L. J. V. Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br. J. Pharmacol. 2002, 137, 504-512.
17. Mettey, Y.; Vierfond, J.-M.; Baudry, M.; Cochet, C.; Sarrouilhe, D. Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CKII. Bioorg. Med. Chem. Lett. 1997, 7, 961-964.
18. Marivingt-Mounir, C.; Sarrouilhe, D.; Mettey, Y.; Vierfond, J.-M. Synthesis of Benzo[f]indolo[2,3-a]quinoliziniums as inhibitors for protein kinase CKII. Pharm. Pharmacol. Commun. 1998, 4, 23-25.
19. Vierfond, J.-M.; Mettey, Y.; Joubin, R.; Miocque, M. Synthèse de Dérivés de la Benzo[c]quinolizine. J. Heterocycl. Chem. 1979, 16, 753-755.
20. Ziegler, C. B. Jr; Moran, D. B.; Fenton, T. J.; Lin, Y. The synthesis and biological activity of 8-Fluoro-9-(4-methyl-1-piperazinyl)-6-oxo-6H-benzo[c] quinolizine-5-carboxylic acid. J. Heterocycl. Chem. 1990, 27, 587-589.
21. Illek, B.; Zhang, L.; Lewis, N. C.; Moss, R. B.; Dong, J. Y.; Fischer, H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am. J. Physiol. 1999, 277, C833-C839.
22. Drumm, M. L.; Wilkinson, D. J.; Smit, L. S.; Worrell, R. T.; Strong, T. V.; Frizzell, R. A.; Dawson, D. C.; Collins, F. S. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991, 254, 1797-1799.
23. Schultz, B. D.; Singh, A. K.; Devor, D. C.; Bridges, R. J. Pharmacology of CFTR chloride channel activity. Physiol. Rev. 1999, 79, S109-S144.
24. Becq, F.; Verrier, B.; Chang, X.-B.; Riordan, J. R.; Hanrahan, J. W. cAMP- and Ca2+-independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs. J. Biol. Chem. 1996, 271, 16171-16179.
25. Kelley, T. J.; Al-Nakkash, L.; Drumm, M. L. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 1995, 13, 657-664.
26. Illek, B.; Fischer, H.; Santos, G. F.; Widdicombe, J. H.; Machen, T. E.; Reenstra, W. W. cAMP-independent activationof CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am. J. Physiol. 1995, 268, C886-C893.
27. Galietta, L. J. V.; Springsteel, M. F.; Eda, M.; Niedzinski, E. J.; By, K.; Haddadin, M. J.; Kurth, M. J.; Nantz, M. H.; Verckman, A. S. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem. 2001, 276, 19723-19728.
28. Gribkoff, V. K.; Champigny, G.; Barbry, P.; Dworetzky, S. I.; Meanwell, N. A.; Lazdunski, M. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. 1994, 269, 10983-10986.
29. Chappe, V.; Mettey, Y.; Vierfond, J.-M.; Hanrahan, J. W.; Gola, M.; Verrier, B.; Becq, F. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br. J. Pharmacol. 1998, 123, 683-693.
30. Bulteau, L.; Derand, R.; Mettey, Y.; Metaye, T.; Morris, M. R.; McNeilly, C. M.; Folli, C.; Galietta, L. J.; Zegarra-Moran, O.; Pereira, M. M.; Jougla, C.; Dormer, R. L.; Vierfond, J.-M.; Joffre, M.; Becq, F. Properties of CFTR activated by the xanthine derivative X-33 in human airway Calu-3 cells. Am. J. Physiol. 2000, 279, C1925-C1937.
31. Eidelman, O.; Guay-Broder, C.; van Galen, P. J.; Jacobson, K. A.; Fox, C.; Turner, R. J.; Cabantchik, Z. I.; Pollard, H. B. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 5562-5566.
32. Ma, T.; Vetrivel, L.; Yang, H.; Pedemonte, N.; Zegarra-Moran, O.; Galietta, L. J.; Verkman, A. S. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J. Biol. Chem. 2002, 277, 37235-37241.
33. Dormer, R. L.; Dérand, R.; McNeilly, C.; Mettey, Y.; Dérand, R.; Bulteau, L.; Vierfond, J.-M.; Gray, M. A.; Galietta, L. J. V.; Morris, M. R.; Pereira, M.; Doull, I. J. M.; Becq, F.; McPherson, M. A. Correction of delF508-CFTR activity with benzoquinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell. Science 2001, 114, 4073-4081.
34. He, Z.; Raman, S.; Guo, Y.; Reenstra, W. W. Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms. Am. J. Physiol. 1998, 275, C958-C966.
35. Dérand, R.; Bulteau-Pignoux, L.; Becq, F. The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site. J. Biol. Chem. 2002, 277, 35999-36004.
36. Olivier, J.-C.; Manceau, J.; Marivingt-Mounir, C.; Mettey, Y.; Vierfond, J.-M.; Couet, W. Photodegradation of a new activator of the Cystic Fibrosis Chloride Channel, the 6-hydroxy-10-chlorobenzo[c]quinolizinium chloride (MPB-07). J. Pharm. Sci. 2002, 91, 1-7.
37. Fozard, A.; Bradsher, C. K. Benzo[c]quinolizinium salts via intramolecular cyclisation. J. Org. Chem. 1966, 31, 2346-2349.
38. Watkin, D. J.; Prout, C. K.; Carruthers, R. J.; Betteridge, P. Crystals; Chemical Crystallography Laboratory, University of Oxford: Oxford, U.K., 1996; issue 10.
39. Watkin, D. J.; Prout, C. K.; Carruthers, R. J.; Betteridge, P. Crystals; Chemical Crystallography Laboratory, University of Oxford: Oxford, U.K., 2002; issue 11.
40. International Tables for X-ray Crystallography; Kynoch Press: Birmingham, U.K., 1974; Vol. IV, Table 2.2B.
41. Altomare, A.; Cascarano, G.; Giacovazzo, G.; Guagliardi, A.; Burla, M. C.; Polidori, G.; Camalli, M. SIR92-A program for automatic solution of crystal structures by direct methods. J. Appl. Crystallogr. 1994, 27, 435.
42. Sheldrick, G. M. SHELXS-86. Program for the solution of crystal structures; University of Göttingen: Germany, 1986.
43. Watkin, D. J.; Prout, C. K.; Pearce, L. J. CAMERON; Chemical Crystallography Laboratory, University of Oxford: Oxford, U.K., 1996.
44. Venglarik, C. J.; Bridges, R. J.; Frizzell, R. A. A simple assay for agonist-regulated Cl and K conductances in salt-secreting epithelial cells. Am. J. Physiol. 1990, 259, C358-C364.